Baricitinib (Olumiant), tofacitinib (Xeljanz) iand upadacitinab (Rinvoq) are drugs classified as JAK inhibitor. They are often used in people who no longer respond to methotrexate. Tofacitinib comes as a pill taken twice a day, while baricitinib or upadacitinib are taken once a day with or without food. Because they inhibit immune responses, they addsto a person's risk of serious infections, cancers, and lymphoma. The drugs will carry a "black box" warning about these risks. The drug will carry a "black box" warning about these risks.